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Screening for Elevated Blood Lead Levels
in Children and PregnantWomen
US Preventive Services Task Force
Recommendation Statement
US Preventive Services Task Force
IMPORTANCE Elevated blood lead levels in children are associated with neurologic effects
such as behavioral and learning problems, lower IQ, hyperactivity, hearing problems, and
impaired growth. In pregnant women, lead exposure can impair organ systems such as the
hematopoietic, hepatic, renal, and nervous systems, and increase the risk of preeclampsia
and adverse perinatal outcomes. Many of the adverse health effects of lead exposure are
irreversible.
OBJECTIVE To update the 2006 US Preventive Services Task Force (USPSTF)
recommendation on screening for elevated blood lead levels in children and pregnant
women.
EVIDENCE REVIEW The USPSTF reviewed the evidence on the benefits and harms of
screening for and treatment of elevated blood lead levels. In this update, an elevated blood
lead level was defined according to the Centers for Disease Control and Prevention reference
level of 5 μg/dL.
FINDINGS The USPSTF found adequate evidence that questionnaires and other clinical
prediction tools to identify asymptomatic children with elevated blood lead levels are
inaccurate. The USPSTF found adequate evidence that capillary blood testing accurately
identifies children with elevated blood lead levels. The USPSTF found inadequate evidence
on the effectiveness of treatment of elevated blood lead levels in asymptomatic children 5
years and younger and in pregnant women. The USPSTF found inadequate evidence
regarding the accuracy of questionnaires and other clinical prediction tools to identify
asymptomatic pregnant womenwith elevated blood lead levels. The USPSTF found
inadequate evidence on the harms of screening for or treatment of elevated blood lead levels
in asymptomatic children and pregnant women. The USPSTF concluded that the current
evidence is insufficient, and that the balance of benefits and harms of screening for elevated
blood lead levels in asymptomatic children 5 years and younger and in pregnant women
cannot be determined.
CONCLUSIONS AND RECOMMENDATION The USPSTF concludes that the current evidence is
insufficient to assess the balance of benefits and harms of screening for elevated blood lead
levels in asymptomatic children. (I statement) The USPSTF concludes that the current
evidence is insufficient to assess the balance of benefits and harms of screening for elevated
blood lead levels in asymptomatic pregnant persons. (I statement)
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T heUSPreventiveServicesTaskForce (USPSTF)makes rec-ommendations about theeffectivenessof specific preven-tivecare services forpatientswithoutobvious relatedsigns
or symptoms.
It bases its recommendations on the evidence of both the
benefits and harms of the service and an assessment of the bal-
ance. The USPSTF does not consider the costs of providing a ser-
vice in this assessment.
TheUSPSTFrecognizes that clinicaldecisions involvemorecon-
siderations than evidence alone. Clinicians should understand the
evidence but individualize decision making to the specific patient
or situation. Similarly, the USPSTF notes that policy and coverage
decisions involve considerations in addition to theevidenceof clini-
cal benefits and harms.
Summary of Recommendations and Evidence
The USPSTF concludes that the current evidence is insufficient to
assess the balance of benefits and harms of screening for
elevated blood lead levels in asymptomatic children (I statement)
(Figure 1).
The USPSTF concludes that the current evidence is insuffi-
cient to assess the balance of benefits and harms of screening
for elevated blood lead levels in asymptomatic pregnant persons.
(I statement)
See theClinical Considerations section for suggestions forprac-
tice regarding the I statements.
Rationale
Importance
Elevated blood lead levels in children are associated with
neurologic effects such as behavioral and learning problems,
lower IQ, hyperactivity, hearing problems, and impaired growth.1-4
In pregnant women, lead exposure can impair organ systems
such as the hematopoietic, hepatic, renal, and nervous systems
and increase the risk of preeclampsia and adverse perinatal
outcomes.5,6 Many of the adverse health effects of lead exposure
are irreversible.1 Thus, the primary benefit of screening may be
in preventing future exposures or exposure of others to environ-
mental sources.
Detection
The USPSTF found adequate evidence that capillary blood testing
accurately identifies children with elevated blood lead levels com-
pared with venous blood testing. The USPSTF found adequate
evidence that questionnaires and other clinical prediction tools to
identify asymptomatic children with elevated blood lead levels
are inaccurate.
The USPSTF found inadequate evidence regarding the accu-
racy of questionnaires andother clinical prediction tools to identify
asymptomatic pregnant womenwith elevated blood lead levels.
Benefits of Early Detection and Intervention or Treatment
The USPSTF found inadequate evidence on the effectiveness of
screening for elevated blood lead levels in asymptomatic children
5 years and younger to improve health outcomes (eg, cognitive or
behavioral problems or learning disorders). The USPSTF found in-
adequateevidenceon theeffectivenessof interventions (eg, coun-
seling and nutritional interventions, residential lead hazard control
measures, or chelation therapy) to improve intermediate (reduc-
tion in blood lead levels) or health outcomes in asymptomatic chil-
dren with elevated blood lead levels.
The USPSTF found inadequate evidence on the effectiveness
of screening for elevated blood lead levels in asymptomatic preg-
nant women to improve health outcomes (eg, cognitive problems
in children, perinatal outcomes, or maternal outcomes). The
USPSTF also found inadequate evidence on whether the effective-
ness of screening varies by gestational age. The USPSTF found
inadequate evidence on the effectiveness of interventions
(eg, counseling and nutritional interventions, residential lead haz-
ard control measures, or chelation therapy) to improve intermedi-
ate (eg, blood lead levels or gestational hypertension) or health
outcomes in pregnant women.
Harms of Early Detection and Intervention or Treatment
TheUSPSTF found inadequate evidence on the harms of screening
for or treatment of elevatedblood lead levels in asymptomatic chil-
dren or pregnant women.
USPSTF Assessment
The USPSTF concludes that the current evidence is insufficient to
assess the balance of benefits and harms of screening for elevated
blood lead levels in asymptomatic children 5 years and younger.
Evidence is lacking, and the balance of benefits and harms cannot
be determined.
The USPSTF concludes that the current evidence is insuffi-
cient to assess the balance of benefits and harms of screening for
elevated blood lead levels in asymptomatic pregnant women. Evi-
dence is lacking, and the balance of benefits and harms cannot be
determined.
Clinical Considerations
Patient Population Under Consideration
This recommendation applies to children 5 years and younger and
pregnant persons without symptoms of elevated blood lead levels
(Figure 2).
Suggestions for Practice Regarding the I Statements
Potential Preventable Burden
Screening for elevated blood lead levels with blood tests or ques-
tionnaires could result in the identification of previously unknown
sources of lead in the community, which could identify risk for lead
exposure and protect other individuals.
Sourcesof leadexposure include leadedgasoline, leadpaint,and
contaminatedwater from leadplumbing.Other sources include liv-
ing with a parent exposed to lead through work, pottery with lead
glaze, and certain food or personal products (eg, candy, herbal and
other folk remedies, or cosmetics).1
Elevatedblood lead levelsprimarily affect childrenwitha lower
socioeconomic status and from minority communities because of
the increased risk of housing-related exposure.1,7
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Potential Harms
Evidence on the harms of screening for elevated blood lead levels
is limited. Potential harms are false-positive capillary blood test re-
sults, anxiety, inconvenience, and financial costs associatedwith re-
turn visits and repeated tests. Children with significantly elevated
blood lead levels might receive chelation therapy, which is associ-
atedwith awide range of harms, including injection site pain or ab-
scess, headache, paresthesia, tremors, rash, neutropenia, eleva-
tion of serum liver transaminase, hypertension, tachycardia, fever,
nausea, vomiting, or other gastrointestinal upset.1
Current Practice
There are no data on the proportion of clinicians who screen for
elevated blood lead levels in children without symptoms.1 The
USPSTF found no data on the prevalence of screening for
elevated blood lead levels in pregnant women in primary care
settings.6 Bright Futures recommends screening in accordance
with state law and universal screening at ages 12 and 24 months
in states with no screening program in place.8 The Medicaid Early
and Periodic Screening, Diagnostic, and Treatment program
requires that all children receive a screening blood lead test at
Figure 1. USPSTF Grades and Levels of Evidence
What the USPSTF Grades Mean and Suggestions for Practice
Grade Definition
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice
B The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or
there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients
based on professional judgment and patient preferences. There is at least moderate certainty
that the net benefit is small.
Offer or provide this service for selected
patients depending on individual
circumstances.
D The USPSTF recommends against the service. There is moderate or high certainty that the service
has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of
benefits and harms cannot be determined.
Read the Clinical Considerations section
of the USPSTF Recommendation
Statement. If the service is offered,
patients should understand the
uncertainty about the balance of benefits
and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care
populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be
strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate
is constrained by such factors as 
the number, size, or quality of individual studies.
inconsistency of findings across individual studies.
limited generalizability of findings to routine primary care practice.
lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large
enough to alter the conclusion.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as
benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature
of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of
the limited number or size of studies.
important flaws in study design or methods.
inconsistency of findings across individual studies.
gaps in the chain of evidence.
findings not generalizable to routine primary care practice.
lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.
USPSTF indicates US Preventive Services Task Force.
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ages 12 and 24 months; children aged 36 to 72 months must
receive a screening blood lead test if they have not been previ-
ously screened for lead poisoning.1
Screening Tests
Blood tests or questionnaires may be used to screen for elevated
blood lead levels.Elevatedblood lead levelscanbedetectedbymea-
suring free erythrocyte or zinc protoporphyrin levels and capillary
or venous blood lead levels. Capillary blood testing is recom-
mended for initial screening.However, false-positive results canoc-
cur if capillary blood samples become contaminated. Patientswith
positive screening results fromcapillaryblood samples shouldhave
confirmatory venous blood testing.1
Questionnaires havebeendeveloped to identify children at in-
creasedriskofelevatedblood lead levels.Themostcommonlyused
questionnaire istheCentersforDiseaseControlandPrevention(CDC)
screening questionnaire. The CDC questionnaire asks 5 questions
about the following: living in or visiting a house built before 1960
withchippingpaintorundergoingrenovation,havingasiblingorclose
contact beingmonitoredor treated for leadpoisoning (definedas a
blood lead level >15 μg/dL), living with an adult exposed to lead
throughworkorhobbies,and livingnear lead-based industry.Aposi-
tive or “I don’t know” answer to any of the questions indicates the
need for a blood lead test.1,7 There are no validated questionnaires
to identify pregnant women at high risk of lead exposure.6
Treatment
Patients with an elevated blood lead level should have confirma-
tory venous blood testing. Management is based on the lead level
and symptoms. Treatment options include residential lead hazard
control measures, educational interventions (eg, counseling on
household dust control measures), environmental interventions
(eg, soil abatement, dust or paint removal, or removal of contami-
nated water sources), chelation therapy, and nutritional interven-
tions. Finding the source of lead exposure is essential in prevent-
ing repeated or future exposures.
In most settings, education and counseling is offered to chil-
dren with blood lead levels ranging from 10 to 20 μg/dL. Some ex-
perts also recommendnutritional counseling for childrenwithblood
lead levels in this range. Residential lead hazard control measures
are usually offered to childrenwith blood lead levels of 20μg/dL or
greater,whilechelation therapy isofferedtochildrenwithblood lead
levels of 45 μg/dL or greater.1
Educational interventions focus on parental counseling about
leadexposure,hygiene,andhouseholddustcontrolmeasures topre-
vent the ingestion of dust and soil. Environmental interventions in-
clude specialized cleaning, repairs, maintenance, soil abatement
(eg, removal and replacement), painting, and temporary contain-
ment of lead hazards.1
Calcium,dietary iron, andother supplementsare thought tode-
crease the intestinal absorption of lead. However, the role of nutri-
tional interventions (ie, supplementation) in reducingblood lead lev-
els remains unclear.1
Chelation therapy is recommended for symptomatic patients
withmoderate or severe lead toxicity. Dimercaprol (or its less toxic
analog, dimercaptosuccinic acid [DMSA], also known as succimer)
is a commonlyusedagent that removes lead fromthebloodandsoft
tissues. Penicillamine is less commonly used.1
Management of elevatedblood lead levels in pregnantwomen
alsovariesdependingonthe lead level andconsistsofeducationand
environmental interventions, nutritional interventions, and chela-
tion therapy.6
Figure 2. Clinical Summary: Screening for Elevated Blood Lead Levels in Children and PregnantWomen
Population
Recommendation 
Children 5 years and younger and pregnant persons
No recommendation.
Grade: I (insufficient evidence)
Screening Tests
Treatment and
Interventions
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please
go to https://www.uspreventiveservicestaskforce.org.   
Elevated blood lead levels can be detected by measuring capillary or venous blood lead levels. Capillary blood testing is
recommended for initial screening. Patients with positive screening results from capillary blood samples should have
confirmatory venous blood testing.
Questionnaires to identify children at increased risk of elevated blood lead levels are poorly accurate. The most commonly
used questionnaire is the Centers for Disease Control and Prevention screening questionnaire.
Treatment options include residential lead hazard control measures, educational interventions (eg, counseling on household
dust control measures), environmental interventions (eg, soil abatement, dust or paint removal, or removal of contaminated
water sources),  nutritional interventions, and chelation therapy. Finding the source of lead exposure is essential in preventing
repeated or future exposures.
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Other Considerations
Research Needs and Gaps
Research is needed to better inform decisions about screening for
elevated blood lead levels in children and pregnant women, such
as the development of validated questionnaires to identify at-risk
populations most likely to benefit from screening. Studies report-
ing intermediate and health outcomes, outcomes in newborns,
and harms in women and infants are needed, as well as studies
evaluating effective interventions for reducing blood lead levels in
pregnant women. Research is also needed to evaluate the effec-
tiveness of treatments for elevated blood lead levels in trials with
adequate sample sizes to inform treatment strategies. However,
randomized trials may not always be appropriate for screening
and environmental interventions because of ethical issues. Well-
designed research studies are needed on the benefits of nutri-
tional supplementation in reducing blood lead levels in children.
Research on newer approaches to detecting elevated blood lead
levels, such as point-of-care testing, that include intraindividual
and interlaboratory reliability would be useful for assessing
screening strategies in children and pregnant women. Different
sources of lead exposure that are now emerging in at-risk com-
munities are not well incorporated into current screening ques-
tionnaires. Research on screening and prevention in these popu-
lations remains limited. Additional research is needed to validate
these potential risk factors in specific geographic locations and
among at-risk populations.
Discussion
Burden of Disease
TheCDCdefinesanelevatedblood lead levelas5μg/dLorgreater.1,6,8
There isnosafe level of leadexposure;however, theblood lead level
servesasaprompt for furtherclinicalmonitoringandtreatment.This
reference rangevalue is basedonpopulationblood lead levels from
NationalHealth andNutritional ExaminationSurveydata.1,2,6,9 Pre-
viously, childrenwith a blood lead level of 10 μg/dL or greaterwere
identified as having an elevated blood lead level.
The prevalence of elevated blood lead levels has greatly de-
creased in thepast4decades.According toNationalHealthandNu-
tritional ExaminationSurveydata and theChildBloodLeadSurveil-
lanceSystem,8.8%ofchildrenaged1 to5yearshadblood lead levels
of 10 μg/dL or greater from 1976 to 1980 and 4.4%of children had
elevatedblood lead levels from1991to1994.By1999to2002,preva-
lence had decreased to 1.6%, and from 2007 to 2010 it was only
0.8%.1However,blood lead levels inyoungerchildren increasedfrom
2007 to 2010, with 3.1% of 1- to 2-year-olds having blood lead lev-
els of 5 μg/dL or greater.1
Risk factors for lead exposure include socioeconomic factors
(eg, lower family income, older housing, and poor nutritional sta-
tus), living near an industry that involves lead, proximity to the
renovation or deterioration of older houses with lead-based
paint, and previously living in countries where lead exposure is
high. The risks vary by race/ethnicity, socioeconomic status, and
housing. From 2007 to 2010, the prevalence of blood lead levels
of 5 μg/dL or greater in children aged 1 to 2 years was 7.7% in non-
Hispanic black children, 3.2% in non-Hispanic white children, and
1.6% in Mexican American children. Prevalence was 3.1% in boys
and 3.2% in girls, and much higher in lower-income populations.
Children living in housing built before 1950 are 5 times more likely
to have blood lead levels greater than 5 μg/dL than children living
in housing built after 1978.1
Elevated levels of lead in the body affect various organ sys-
tems, including the cardiovascular, renal, and hepatic systems,
with most symptoms occurring at blood lead levels of 50 μg/dL or
greater. Very high levels of inorganic lead exposure may result in
death or long-term neurologic symptoms in children. However,
behavioral disorders are associated with blood lead levels as low
as 5 μg/dL in young children.10
Adverse effects of very highmaternal blood lead levels during
pregnancy include abortion, stillbirth, preterm delivery, decreased
neonatal head circumference, and decreased birthweight. Studies
also suggest thatmildly elevatedmaternal blood lead levels during
pregnancy may be associated with increased risk for spontaneous
abortion, gestational hypertension, and adverse effects on fetal
growth. Although very high blood lead levels during pregnancy are
harmful, theadverseeffectsof elevatedantepartumblood lead lev-
els on the fetus, at least for the range of exposure typically found in
the United States, have not been established.11
Scope of Review
The USPSTF commissioned a systematic evidence review to
update its 2006 recommendation12 on screening for elevated
blood lead levels in children and pregnant women. The USPSTF
focused on evidence on the benefits and harms of screening for
and treatment of elevated blood lead levels. In this update, an
elevated blood lead level was defined according to the CDC refer-
ence level of 5 μg/dL. The use of blood tests for diagnosis or man-
agement is outside the scope of this recommendation.
Accuracy of Screening Tests
Four fair-quality studies (n = 1431) conducted in urban areas of the
United States found that capillary blood testing had a sensitivity of
87% to 91% and specificity of greater than 90% (range, 92%-
99%) for identifyingelevatedblood lead levels, usingvenousblood
testing as the reference standard.1
Five fair-quality studies (n = 2265) using the threshold of 1 or
more positive answers on the CDC screening questionnaire re-
ported a pooled sensitivity of 48% (95% CI, 31.4%-65.6%) and
pooledspecificityof58%(95%CI,39.9%-74.0%)for identifyingchil-
drenwith a venousblood lead level of 10μg/dLor greater. Four fair-
quality studies (n = 4608) using versions of theCDCquestionnaire
modified for specific populations or settings did not demonstrate
improved accuracy (sensitivity range, 25%-68%; specificity range,
49%-58%).1
One fair-quality observational study evaluated the accuracy of
aquestionnaire to identifypregnantwomenwithelevatedblood lead
levels. The study used 4 of the 5 questions from the CDC question-
naire (excludingthequestionon industrial leadexposure),whichwas
originally designed to identify at-risk children.6 The study showed
thatwomenwith a positive response to at least 1 of the4questions
weremore likely to have elevatedblood lead levels than thosewho
answered negatively to all 4 questions (relative risk, 2.39 [95% CI,
1.17-4.89];P = .01). TheCDCquestionnairehadasensitivityof75.7%
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and a sensitivity of 46.2% for pregnant women. The most predic-
tive single itemwas “home built before 1960.”6
Effectiveness of Early Detection and Treatment
No studies directly compared the effectiveness of screening vs no
screening for elevated blood lead levels in children 5 years and
younger or in pregnant women on health outcomes.
Seven randomized clinical trials (RCTs) examined interven-
tions for elevated blood lead levels.1 One large, good-quality RCT
(n = 780) found that chelation therapywithDMSA in childrenwith
a mean blood lead level of 20 to 45 μg/dL was associated with re-
ducedblood lead levels comparedwithplaceboat 1week,6months,
and 1 year, but not at 4.5 to 6 years of follow-up.1,13 One fair-quality
RCT found no differences between chelation therapy and placebo
in blood lead levels at 1 or 6 months.14 There was limited evidence
from 2 poor-quality studies to determine the effects of nutritional
supplementation.15,16Three fair-qualityRCTs fromtheUnitedStates
and Australia found no clear effects of home lead abatement in re-
ducing blood lead levels.17-19
One good-quality randomized study found no differences be-
tween chelation therapy and placebo in neuropsychological out-
comes, despite a reduction in blood lead levels following chelation
therapy.20 Therewas no evidence on the effects of counseling and
nutritional interventions or residential lead hazard control mea-
sures on health outcomes in asymptomatic children with elevated
blood lead levels.1
One fair-quality RCT of healthy pregnant women (mean base-
line lead level, 4 μg/dL) conducted in Mexico found that calcium
supplementationwasassociatedwithreducedblood lead levelscom-
paredwith placebo (difference, 11%;P = .004 [levels in each group
not reported]).21 Effects were more pronounced in women with
baselineblood lead levels greater than5μg/dL. Study limitations in-
clude unclear methods of allocation, lack of blinding of patients or
outcome assessors, and population differences at baseline such as
dietary calcium intake.1,21 No studies reported on health outcomes
in asymptomatic pregnant women after interventions to reduce
blood lead levels.1
Potential Harms of Screening and Treatment
The USPSTF found no studies that evaluated the harms of screen-
ing for elevated blood lead levels in children.
Onegood-quality study found that children treatedwithDMSA
hadasmallbutstatistically significantdecrease inheightgrowthover
34months(differenceof0.35cm[95%CI,0.05-0.72cm]).Thestudy
also foundmarginallypoorer scoresonattentionandexecutive func-
tion tests at age 7 years.20 One poor-quality study of chelation
therapywith penicillamine reported associated adverse events, in-
cluding leukopenia, thrombocytopenia, hives and maculopapular
rash,urinary incontinence, abdominalpain, anddiarrhea.22Nostud-
ies reported on the harms of counseling, nutritional interventions,
or residential lead hazard control measures.1
The USPSTF found no studies that evaluated the harms of
screening for and treatment of elevated blood lead levels in preg-
nant women.
Estimate ofMagnitude of Net Benefit
TheUSPSTFfoundadequateevidencethatquestionnairesandother
clinical prediction tools to identify asymptomatic children with el-
evated blood lead levels are inaccurate. The USPSTF found ad-
equateevidencethatcapillarybloodtestingaccurately identifieschil-
drenwithelevatedblood lead levels. TheUSPSTF found inadequate
evidence on the effectiveness of treatment of elevated blood lead
levels in asymptomatic children 5 years and younger in improving
intermediate or health outcomes.
The USPSTF found inadequate evidence regarding the accu-
racy of questionnaires and other clinical prediction tools to iden-
tify asymptomatic pregnant women with elevated blood lead lev-
els. The USPSTF found inadequate evidence on the effectiveness
of treatment of elevated blood lead levels in asymptomatic preg-
nant women in improving intermediate or health outcomes. The
USPSTF found inadequate evidence on the harms of screening for
or treatment of elevated blood lead levels in asymptomatic chil-
dren or pregnant women.
Therefore, the USPSTF concludes that the current evidence is
insufficient, and that the balance of benefits and harms of screen-
ing for elevated blood lead levels in asymptomatic children 5 years
and younger and in pregnant women cannot be determined.
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from October 30 to
December 3, 2018. Many comments expressed concern about
at-risk populations. In response, the USPSTF added information
about emerging risk factors in the Clinical Considerations and
Research Needs and Gaps sections. Some comments sought clarifi-
cation of whom the recommendation applies to. The USPSTF clari-
fied that the recommendation applies to “asymptomatic” popula-
tions in the Patient Population Under Consideration section.
Update of Previous USPSTF Recommendation
In 2006, the USPSTF concluded that the evidence was insuffi-
cient to recommend for or against routine screening for elevated
blood lead levels in asymptomatic children aged 1 to 5 years at
increased risk (I recommendation).12 The USPSTF recommended
against routine screening for elevated blood lead levels in asymp-
tomatic children aged 1 to 5 years at average risk (D recommenda-
tion). The USPSTF also recommended against routine screening
for elevated blood lead levels in asymptomatic pregnant women
(D recommendation).
The understanding of lead exposure has changed considerably
since 2006. No safe level of lead exposure has been established,
and since the previous USPSTF recommendation, the reference
level to identify children with elevated blood lead levels has been
lowered from 10 to 5 μg/dL. Other sources of lead that could affect
blood lead levels may now be more prevalent than in 2006, and
these sources were not studied in the currently available evidence.
There is a lack of evidence on interventions that can be done in
a clinical setting that would improve health outcomes. A change
in the context and applicability of older evidence resulted in the
USPSTF assessing the evidence on harms of treatment as inad-
equate. As a result, the USPSTF determined that the current evi-
dence is insufficient to assess the balance of benefits and harms of
screening for elevated blood lead levels, leading the USPSTF to
issue an I statement for both populations.
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Recommendations of Others
The American Academy of Family Physicians recommends against
routine screening for elevated blood lead levels in asymptomatic
children aged 1 to 5 years at average risk, and found insufficient evi-
dence on screening in children at increased risk.23 The American
Academy of Pediatrics recommends screening based on federal,
state, and local requirements; in children living in high-prevalence
areas (communities with25% of housing built before 1960 or a
prevalence of blood lead levels5 μg/dL of5%); in children with
identified lead hazards or living in a home built before 1960 that is
in poor repair or renovated in the past 6months; or in children who
are immigrants, refugees, or internationally adopted.24 The Medic-
aid Early and Periodic Screening, Diagnostic, and Treatment pro-
gram requires that all children receive a screening blood lead test at
ages 12 and 24 months; children aged 36 to 72 months must
receive a screening blood lead test if they have not been previously
screened for lead poisoning.1 Bright Futures recommends screen-
ing in accordance with state law and universal screening at ages 12
and 24 months in states with no screening program in place.8 The
CDC and the American College of Preventive Medicine recommend
screening in children at increased risk for lead exposure.25
The American Academy of Family Physicians recommends
against routine screening for elevated blood lead levels in preg-
nant women without symptoms.23 The CDC and the American
College of Obstetricians and Gynecologists recommend targeted
screening during pregnancy and lead testing in pregnant and lac-
tating women with 1 or more risk factors for lead exposure, such
as environmental or occupational exposures or pica.26
ARTICLE INFORMATION
TheUS Preventive Services Task Force (USPSTF)
members: Susan J. Curry, PhD; Alex H. Krist, MD,
MPH; Douglas K. Owens, MD, MS; Michael J. Barry,
MD; Michael Cabana, MD, MA, MPH; Aaron B.
Caughey, MD, PhD; Chyke A. Doubeni, MD, MPH;
JohnW. Epling Jr, MD, MSEd; Alex R. Kemper, MD,
MPH, MS; Martha Kubik, PhD, RN; C. Seth
Landefeld, MD; Carol M. Mangione, MD, MSPH; Lori
Pbert, PhD; Michael Silverstein, MD, MPH; Melissa
A. Simon, MD, MPH; Chien-Wen Tseng, MD, MPH,
MSEE; John B. Wong, MD.
Affiliations of TheUS Preventive Services Task
Force (USPSTF)members:University of Iowa,
Iowa City (Curry); Fairfax Family Practice Residency,
Fairfax, Virginia (Krist); Virginia Commonwealth
University, Richmond (Krist); Veterans Affairs Palo
Alto Health Care System, Palo Alto, California
(Owens); Stanford University, Stanford, California
(Owens); Harvard Medical School, Boston,
Massachusetts (Barry); University of California,
San Francisco (Cabana); Oregon Health & Science
University, Portland (Caughey); University of
Pennsylvania, Philadelphia (Doubeni); Virginia Tech
Carilion School of Medicine, Roanoke (Epling);
Nationwide Children’s Hospital, Columbus, Ohio
(Kemper); Temple University, Philadelphia,
Pennsylvania (Kubik); University of Alabama at
Birmingham (Landefeld); University of California,
Los Angeles (Mangione); University of
Massachusetts Medical School, Worcester
(Pbert); Boston University, Boston, Massachusetts
(Silverstein); Northwestern University, Evanston,
Illinois (Simon); University of Hawaii, Honolulu
(Tseng); Pacific Health Research and
Education Institute, Honolulu, Hawaii (Tseng);
Tufts University, Medford, Massachusetts
(Wong).
Accepted for Publication:March 7, 2019.
Author Contributions:Dr Curry had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis. The USPSTFmembers contributed
equally to the recommendation statement.
Conflict of Interest Disclosures: All authors have
completed and submitted the ICMJE Form for
Disclosure of Potential Conflicts of Interest. Authors
followed the policy regarding conflicts of interest
described at https://www.
uspreventiveservicestaskforce.org/Page/Name/
conflict-of-interest-disclosures. All members
of the USPSTF receive travel reimbursement and an
honorarium for participating in USPSTFmeetings.
Funding/Support: The USPSTF is an independent,
voluntary body. The US Congress mandates
that the Agency for Healthcare Research and
Quality (AHRQ) support the operations of
the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted
in the following: development and review of the
research plan, commission of the systematic
evidence review from an Evidence-based
Practice Center, coordination of expert review and
public comment of the draft evidence report and
draft recommendation statement, and the writing
and preparation of the final recommendation
statement and its submission for publication.
AHRQ staff had no role in the approval of the
final recommendation statement or the decision
to submit for publication.
Disclaimer: Recommendations made by the
USPSTF are independent of the US government.
They should not be construed as an official position
of AHRQ or the US Department of Health and
Human Services.
Additional Contributions:We thank Iris
Mabry-Hernandez, MD, MPH (AHRQ), who
contributed to the writing of themanuscript, and
Lisa Nicolella, MA (AHRQ), who assisted with
coordination and editing.
REFERENCES
1. Cantor A, Hendrickson R, Blazina I, Griffin J,
Grusing S, McDonaghM. Screening for Elevated
Blood Lead Levels in Children: A Systematic Review
for the U.S. Preventive Services Task Force: Evidence
Synthesis No. 174. Rockville, MD: Agency for
Healthcare Research and Quality; 2019. AHRQ
publication 18-05245-EF-1.
2. Advisory Committee on Childhood Lead
Poisoning Prevention. Low Level Lead Exposure
Harms Children: A Renewed Call for Primary
Prevention. Atlanta, GA: Centers for Disease Control
and Prevention; 2012.
3. Tchounwou PB, Yedjou CG, Patlolla AK,
Sutton DJ. Heavymetal toxicity and the
environment. Exp Suppl. 2012;101:133-164.
4. Cantor AG, Hendrickson R, Blazina I, Griffin J,
Grusing S, McDonaghMS. Screening for elevated
blood lead levels in childhood and pregnancy:
updated evidence report and systematic review for
the US Preventive Services Task Force [published
April 16, 2019]. JAMA. doi:10.1001/jama.2019.1004
5. Flora G, Gupta D, Tiwari A. Toxicity of lead:
a reviewwith recent updates. Interdiscip Toxicol.
2012;5(2):47-58. doi:10.2478/v10102-012-0009-2
6. Cantor A, McDonaghM, Blazina I, Griffin J,
Grusing S, Hendrickson R. Screening for Elevated
Blood Lead Levels in Pregnant Women: A Systematic
Review for the U.S. Preventive Services Task Force:
Evidence Synthesis No. 175. Rockville, MD: Agency for
Healthcare Research and Quality; 2019. AHRQ
publication 18-05245-EF-2.
7. Lanphear BP, WeitzmanM, Eberly S. Racial
differences in urban children’s environmental
exposures to lead. Am J Public Health. 1996;86(10):
1460-1463. doi:10.2105/AJPH.86.10.1460
8. Hagan JF, Shaw JS, Duncan PM, eds. Bright
Futures: Guidelines for Health Supervision of Infants,
Children, and Adolescents. 4th ed. Elk Grove Village,
IL: American Academy of Pediatrics; 2017.
9. Centers for Disease Control and Prevention.
Screening Young Children for Lead Poisoning:
Guidance for State and Local Public Health Officials.
Atlanta, GA: Centers for Disease Control and
Prevention; 1997.
10. Centers for Disease Control and Prevention
(CDC). Standard surveillance definitions and
classifications. CDCwebsite. https://www.cdc.gov/
nceh/lead/data/definitions.htm. November 18,
2016. Accessed February 22, 2019.
11. Centers for Disease Control and Prevention.
Guidelines for the Identification andManagement of
Lead Exposure in Pregnant and Lactating Women.
Atlanta, GA: Centers for Disease Control and
Prevention; 2010.
12. US Preventive Services Task Force. Screening
for Elevated Blood Lead Levels in Children and
Pregnant Women: U.S. Preventive Services Task
Force Recommendation Statement. Rockville, MD:
US Preventive Services Task Force; 2006.
13. Treatment of Lead-Exposed Children (TLC) Trial
Group. Safety and efficacy of succimer in toddlers
with blood lead levels of 20-44microg/dL. Pediatr
Res. 2000;48(5):593-599. doi:10.1203/
00006450-200011000-00007
14. O’Connor ME, Rich D. Children with moderately
elevated lead levels: is chelation with DMSA
helpful? Clin Pediatr (Phila). 1999;38(6):325-331.
doi:10.1177/000992289903800602
Clinical Review& Education US Preventive Services Task Force USPSTF Recommendation: Screening for Elevated Blood Lead Levels in Children and Pregnancy
1508 JAMA April 16, 2019 Volume 321, Number 15 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 08/05/2019
15. Markowitz ME, Sinnett M, Rosen JF.
A randomized trial of calcium supplementation for
childhood lead poisoning. Pediatrics. 2004;113(1 Pt
1):e34-e39. doi:10.1542/peds.113.1.e34
16. Wolf AW, Jimenez E, Lozoff B. Effects of iron
therapy on infant blood lead levels. J Pediatr. 2003;
143(6):789-795. doi:10.1067/S0022-3476(03)
00540-7
17. Boreland F, Lesjak M, Lyle D. Evaluation of home
lead remediation in an Australian mining
community. Sci Total Environ. 2009;408(2):202-208.
doi:10.1016/j.scitotenv.2009.10.013
18. BrownMJ, McLaine P, Dixon S, Simon P.
A randomized, community-based trial of home
visiting to reduce blood lead levels in children.
Pediatrics. 2006;117(1):147-153. doi:10.1542/peds.
2004-2880
19. Nicholson JS. A community-based intervention
for low-income families to reduce children’s blood
lead levels between 3-9.9 μg/dL. Child Health Care.
2017;47(4):379-396. doi:10.1080/02739615.2017.
1370673
20. RoganWJ, Dietrich KN,Ware JH, et al;
Treatment of Lead-Exposed Children Trial Group.
The effect of chelation therapy with succimer on
neuropsychological development in children
exposed to lead.N Engl J Med. 2001;344(19):1421-
1426. doi:10.1056/NEJM200105103441902
21. EttingerAS,Lamadrid-FigueroaH,Téllez-RojoMM,
et al. Effect of calcium supplementation on blood
lead levels in pregnancy: a randomized placebo-
controlled trial. Environ Health Perspect. 2009;117(1):
26-31. doi:10.1289/ehp.11868
22. ShannonM, Graef J, Lovejoy FH Jr. Efficacy
and toxicity of D-penicillamine in low-level lead
poisoning. J Pediatr. 1988;112(5):799-804. doi:10.
1016/S0022-3476(88)83212-8
23. American Academy of Family Physicians
(AAFP). Clinical preventive services
recommendation: lead poisoning. AAFP website.
https://www.aafp.org/patient-care/clinical-
recommendations/all/lead-poisoning.html.
December 2006. Accessed February 22, 2019.
24. Council on Environmental Health. Prevention
of childhood lead toxicity. Pediatrics. 2016;138(1):
20161493. doi:10.1542/peds.2016-1493
25. LaneWG, Kemper AR; American College of
Preventive Medicine. American College of
Preventive Medicine Practice Policy Statement:
screening for elevated blood lead levels in children.
Am J Prev Med. 2001;20(1):78-82. doi:10.1016/
S0749-3797(00)00257-9
26. Committee on Obstetric Practice. Committee
opinion No. 533: lead screening during pregnancy
and lactation.Obstet Gynecol. 2012;120(2, pt 1):416-
420.
USPSTF Recommendation: Screening for Elevated Blood Lead Levels in Children and Pregnancy US Preventive Services Task Force Clinical Review& Education
jama.com (Reprinted) JAMA April 16, 2019 Volume 321, Number 15 1509
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 08/05/2019
